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Abstract 
Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia and a major risk factor for 
stroke. The number of patients with AF is predicted to increase in the next few decades. AF 
has also negative impact on quality of life as well as it significantly increases the risk of 
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As the stroke is a pivotal outcome of AF, its prevention with the use of anticoagulation 
therapy constitutes an important component of AF management. The decision on oral 
anticoagulants (OACs) prescription should be based on appropriate risk stratification to allow 
comprehensive assessment of benefit/hazard ratio of stroke and bleeding along with patients’ 
preference.  
Several risk scores for stroke and bleeding as well as for stroke and systemic embolism have 
been developed, mainly in patients on vitamin K antagonists (VKAs). AF guidelines stress the 
need for repetitive evaluation of thromboembolic and bleeding risks to tailor optimal AF 
management. Indeed, risk is not a static ‘one off’ process and it should be adjusted for 
dynamic nature of risk factors. However, most risk scores are calculated according to baseline 
characteristics of patients, but the older patients ge , the more comorbidities they acquire, 
which influences stroke risk significantly. Hence, the default management of every patient 
with AF should include a regular reassessment of str ke and bleeding risk factors. 
Keywords: atrial fibrillation, gastrointestinal bleeding, intracranial haemorrhage, major 




Atrial fibrillation (AF) is the most frequently encountered heart rhythm disorder in clinical 
practice and the number of patients with AF is anticipated to increase over the next few 
decades.1 AF is also associated mainly with significant risk of stroke and systemic 
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AF management comprises both therapies with prognostic impact (anticoagulation and 
treatment of cardiovascular conditions) and symptomatic benefit. However, the decision on 
prescription of oral anticoagulants (OACs) should be based on risk assessment in order to 
implement appropriate management.4  
Stroke prevention is central to AF management.  Concepts and approaches to stroke 
prevention have changed considerably over the last decade so as to implement optimal 
thromboprophylaxis.2  Several stroke and bleeding risk scores as well as c inical risk scores 
for stroke and systemic embolism have been developed, mainly in patients on vitamin K 
antagonist (VKA).5   
The majority of current guidelines recommend the us of CHA2DS2-VASC [congestive heart 
failure, hypertension, age ≥75 (doubled), diabetes mellitus, prior stroke or transient ischemic 
attack (doubled), vascular disease, age 65 to 74, female] and HAS-BLED [hypertension (i.e. 
uncontrolled blood pressure), abnormal renal/liver function, stroke, bleeding history or 
predisposition, labile INR (if on warfarin), elderly (e.g. age >65, frail condition), drugs (e.g. 
aspirin, NSAIDs)/alcohol concomitantly]  scores to assess the risk of ischemic stroke and 
major bleeding of AF patients, respectively.6,7   
Given that the default should be to offer stroke prvention unless the patient is ‘low risk’, 
guidelines have evolved to suggest that OACs should be considered for AF patients with a 
CHA2DS2-VASC  score 1 or more (men) or 2 or more (women).
8 This is driven by the positive 
net clinical benefit (when balancing the risk of stroke versus the risk of bleeding) of systemic 
anticoagulation, by means of vitamin K antagonists (VKA, e.g. warfarin) and particularly the 
non-VKA oral anticoagulants (NOACs) which offer relative efficacy, safety and convenience 
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This review article aims to provide an overview of the dynamic nature of stroke and bleeding 
risk factors and its impact on decision-making for AF stroke prevention. In this review paper, 
we aim to describe studies carried out over the last 10 years to inform future longitudinal 
studies and the need for creating new, comprehensiv guidelines. 
 
Search strategy  
We investigated publications on AF risk assessment and the impact of their dynamic changes 
from the last 10 years using MEDLINE and EMBASE bibliography databases electronic 
search. Language of the papers was restricted to English. In addition, we manually checked 
specified references of the included publications. 
 
Individualization of risk stratification 
Net clinical benefit set a basis of the AF management and was introduced to quantify the 
balance between risk of ischemic stroke (IS)  and risk of intracranial hemorrhage (ICH) with 
the use oral anticoagulant therapy (OAC).10 The study of Banerjee at al. showed not only the 
superiority of NOACs over warfarin, but also stress that when the risk of stroke is truly low, 
the net clinical benefit of ischemic stroke preventio  does outbalance the risk of intracranial 
hemorrhage.10 
Eckman et al. modelled the use of warfarin for prevention of thromboembolic stroke in 
patients with AF, in relation to the incidence of warfarin-associated intracerebral hemorrhage, 
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stroke.11 This threshold for NOAC use may be even lower (>0.9% stroke rate per year), 
predominantly due to significantly lower risk of intracranial bleeding compared to warfarin.11. 
Compared with warfarin, the RE-LY trial showed non-inferiority and superiority of 
dabigatran 110 mg BID with regard to reduction of stroke and systemic embolism and 
hemorrhage, respectively.12 Alike, compared with warfarin, dabigatran 150 mg BID showed 
superiority and non-inferiority respectively for stoke/systemic embolism and major 
hemorrhage.12 In the RELY trial, the drug dose (dabigatran 150 mg and 110 mg BID) was 
assigned to a patient by randomization. In the subsequent analysis form the RELY, it was 
suggested that an individually tailored dose of dabig tran, based on estimation of absolute 
benefit and harm, may be more optimal for the patients.13  EMA (European Medicines 
Agency) and European experts recommend the use of both doses of dabigatran (150 mg or 
110 mg BID) as per EU label.13 In contrast, the FDA (Food and Drug Administration) did not 
approve the use of dabigatran 110 mg BID arguing that dabigatran 150 mg is superior to 
warfarin for stroke prevention (even though it may be associated with more major, but non-
fatal bleeding), while AF-related thromboembolic stroke remains the most feared and 
devastation complication of AF and the second cause of d ath worldwide.12,14,15 This 
highlights the importance of patients’ involvement in he treatment and decision-making 
process, ie. shared decision- making (SDM).16  This requires partnership between patients 
(and families, where appropriate) and clinicians that considers patients’ values and 
preferences alongside medical evidence to make the best decisions for a given patient in a 
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Changes in stroke and bleeding risks 
Many stroke risk scores have been calculated according to various baseline characteristics of 
studied population. However, risk is not a static ‘one off’ process and should be adjusted for 
the dynamic nature of risk factors. Hence, risk asses ment of AF patients should be updated 
and regularly reassessed.  
There are some variables which will increase with time or even annually such as age and it 
concerns all patients. Others might occur incidentally e.g. incident hypertension, or the rapid 
onset of diabetes mellitus, vascular disease or even xacerbation of comorbidities leading to 
congestive heart failure, stroke or transient ischemic attack may appear in many patients.17 
Aforementioned factors have a significant impact on he CHA2DS2-VASc scale increasing the 
overall score , which reflects on changing the category of stroke risk , and total ischemic 
stroke rate. Nevertheless, the risk of stroke is often only assessed based on the baseline score 
instead of patient’s current clinical condition without taking into account additional factors 
that change over time. Indeed, the overall risk score at baseline may include clinical incidents 
which happened remotely and currently have no significa t effect on the patient's condition.17  
 
Stroke risk 
Chao et al18 first proposed that the assessment of stroke risk should address the dynamic 
nature of these risk factors, by comparing the predictive value of CHA2DS2-VASc score  
at baseline, follow-up and the change in the score (‘D lta CHA2DS2-VASc score’). There 
were investigated a total of 31,039 AF patients who ere not treated with anti-platelet agents 
or OACs without any additional risk factors according to the CHA2DS2-VASc score with the 
exception of age and sex. Ischemic stroke occurred in 4,103 patients during 171,956 person-
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CHA2DS2-VASc score ≥1 were observed in 89,4% of participants compared with 54.6% 
among patients who had not experienced ischemic stroke. Moreover 2,643 patients (64,4%) 
acquired >1 new-onset comorbidity and hypertension was the most common one. Delta 
CHA2DS2-VASc score turned out to be a relevant prognosis of i chemic stroke which was 
more reliable than baseline or even follow-up CHA2DS2-VASc scores.
18  
This finding was independently confirmed by Yoon et al. using data from the National Health 
Insurance Service (NHIS) database of Korea. There wre studied 167,262  
non-valvular AF patients aged ≥18 years, who have not been treated with anticoagulants 
before.19 At the beginning, the percentage of patients classified as ‘low’, ‘intermediate’ or 
‘high risk’ according to CHA2DS2-VASc score were 15.4, 10.6 and 74.0%, respectively.  
During 10- years of observation, a group of patients previously classified as ‘low-risk’ 
(46,6%) as well as a group of ‘intermediate risk’ (72%) were reassessed and recategorized 
into higher risk categories.19 Among patients initially assigned as low-risk, therate of annual 
ischemic strokes was higher in the group which was reclassified to ‘intermediate’ or even 
‘high-risk’ compared to those whose risk strata hadnot changed (1.17 per 100 person-years, 
p<0.001; 1.44 per 100 person-years, p 1⁄4 0.048; 0.29 per 100 person-years respectively).19  
Hence, up-to-date CHA2DS2-VASc scores and their change with time in the follow-up 
assessment constitute a valuable predictor for ischemic stroke.19 
 
Bleeding risk 
Bleeding risk assessment is to address modifiable bleeding risk factors, and then to ‘flag up’ 
those at high risk for more frequent reviews and early follow-up (e.g. 4 weeks, rather than 4-6 
months).20 Of the various bleeding risk factors available, th HAS-BLED score has been 
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A strategy that simply focuses on modifiable bleeding risk factors alone is inferior for 
bleeding risk assessment, compared to the use of a form l bleeding risk score such as the 
HAS-BLED score.22,23,24 Using a biomarker based assessment of bleeding risk fo  predicting 
remote outcomes also does not show any advantage over c nventional clinical risk 
assessment.25 
These limitations of ‘one off’ bleeding risk assessment reflect the highly dynamic nature  
of bleeding risk. In the study by Chao et al26 which analyzed a total of 19,566 AF patients 
who have been treated with warfarin and HAS-BLED score from the baseline of ≤ 2. There 
were observed 3,032 major bleeds during 93,783 person-years of follow-up.26 The thorough 
analysis of accuracy of the baseline, delta HAS-BLED score, follow-up and the sum of 
modifiable risk factors in prediction of major bleeding incidents were conducted. In the 
baseline the mean score was 1.43 which rose up to 2.45 with an average ‘delta HAS-BLED’ 
score of 1.03. Among patients who experienced major bleeding, 76.6% had a ‘delta HAS-
BLED’ score ≥1 (p < 0.001) and only in 38.2% of patients the HAS-BLED score did not 
change.26 The figure 1 presents that the follow-up (0.63, 95% CI = 0.62-0.64)  and or delta 
HAS-BLED (0.62, 95% CI = 0.61-0.63) are better predictors of major bleeding than baseline 
HAS-BLED score (0.54, CI = 0.53-0.55).26  Moreover, the amount of modifiable risk factors 
from the baseline was not prognostic for major bleeding events ( 0.49, 95% CI = 0.48-0.50).26 
Hence, stroke and bleeding risk assessment should be regularly performed, at every patient 
contact.  The proper way to use the scoring schemes is to reassess stroke and bleeding risks 
and in the case of the latter, to correct the modifiable risk factors appropriately.27  
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Dynamic nature of modifiable risk factors 
As patients get older, they accumulate more comorbidities. Most patients with AF who 
experienced ischemic stroke develop  more than one new stroke risk factor before ischemic 
stroke occurred. 18 The patient’s clinical risk profile changes over time and this change has 
been shown to have better prediction ability for their respective risk than simply relying on 
the baseline score values. Hence, neither thromboemlic nor bleeding risks are static and 
must be reassessed regularly.28 
Despite ease-to-use tools, such as e.g. the GRASP-AF29,that can help physicians to assess 
regularly the risk of stroke and subsequently introduce anticoagulation, the ‘real-life data’ 
from primary care practice show very low use of OAC (approximately 50% ) in many AF 
patients. Importantly, guideline-adherent anticoagul tion significantly reduces the risk of 
stroke and improves survival at 1 year.29 
The duration of hypertension sets important dynamic factor. In the study of Kim et al30. a total 
of 246 459 non-valvular AF patients who have not been treated with anticoagulants before 
were recruited from Korea National Health Insurance Service (NHIS) database (2005–
2015)30. The study aimed to assess the risk of ischemic stroke depending on the duration of 
hypertension and systolic blood pressure (SBP) levels. The study showed that the increase of 
hypertension duration was significantly associated with the increased risk of ischemic stroke. 
Nevertheless, the influence of chronic hypertension can be decreased by long-term tight SBP 
control during the whole time of hypertension coexistence.30 
Another study by Chao et al31, which aimed to provide insights into the optimal assessment of 
age and incident comorbidities, stressed the heterogeneity of ischemic stroke risk among 
patients with AF. The cohort study included 31 039 and 39 020 patients with AF and without 
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excluding sex and age, respectively31. The differentiated population was investigated anthe 
risk of ischemic stroke in the certain age groups were assessed according to the following 
approaches: (a) the ‘conventional way’ which was baed on baseline risk factors and age, (b) 
‘dynamic method’ which included an evaluation of patients after the occurrence of new 
comorbidities, (c) an ‘ideal method’ which set an evaluation of patients after the  occurrence 
of new comorbidities and adjustment the stroke risk to the proper age when stroke appeared. 
Finally, the study showed that the age constitutes an important and independent component of 
ischemic stroke risk whereas the overall score is non-homogenous and influenced by various 
factors31. Hence, in patients with AF the age thresholds for the use of NOACs differed due to 
individual various risk factors despite having identical number of points in CHA2DS2-VASC  
score (except for sex).31 Moreover,  the conventional risk assessment based on baseline risk 
per se may overestimate ischemic stroke risk, while use of the ideal method may provide 
better and more accurate assessment of the age threshold when NOAC use should be 
considered.31 
 
Another study by Chao et al. identified 14 606 patients with newly diagnosed AF and a 
CHA2DS2-VASc score of 0 who did not receive antiplatelets or OACs.  The Kaplan–Meier 
method were used to plot cumulative incidence curves for increases in CHA2DS2 -VASc 
scores (Figure 2)32 Accordingly, in up to 36,6% AF patients during an average follow-up of 
3,24 years at least 1 new risk factor were noted. In men, the accumulated frequency of an 
increment in CHA2DS2-VASc score to 1 or even more was 16.1%(95% CI, 15.2% to 
16.9%), 24,5% CI, 23.5% to 25.5%)  and 49.1%(CI, 47.8% to 50.3%) at 1 year, 2 years and 
7 years, respectively.32 In women the aforementioned increment in CHA2DS2-VASc score 
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49.9% (CI, 48.4% to 51.4%) at 1 year, 2 years and 7 years, respectively (Figure 2).32  
Figure 2 also presents the amount of ischemic strokes and deaths in each period. 32 
The aforementioned study conducted by Chao et al. was extended with the aim of estimating 
of reasonable timing interval at which stroke risk should be reassessed for such AF patients.33 
They studied 14,606 AF patients without prior anti-platelet or OACS treatment whose 
baseline CHA2DS2-VASc score were 0 for male or 1 for female group, who were monitored 
and adjusted to the incident of ischemic stroke or death by the end of 31 December 2011.33 
The results showed that the CHA2DS2-VASc score rises yearly in approximately 12% of AF 
patients originally categorized in the ‘low- risk’ group, with most showing a risk change 
occurring in approximately 4 months.  Also, of those who sustained an ischaemic stroke, 
approximately 80% of these had a change in their stroke risk profile on average 4 months 
prior to the stroke.  Consequently, the authors suggested that amongst low risk patients, a 
reassessment of stroke risk at approximately four months was a reasonable timing period, to 
enable stroke prevention therapy with OACs to be appro riately prescribed.33 
Pritchett et al. published a systematic review of studies published till July 2017 about  
interferences made to improve appropriate OAC prescription for stroke prevention in patients 
with AF.34 The study confirms that interventions such as education of health care 
professionals, implementation of local guidelines, interdisciplinary medical care programs 
educating both Health Care Practitioners and patients a d persuasive interventions utilizing 
peer- group experts, can be effective in improving prescription of OACs.34 It was also state 
that real prescription of anticoagulants in order to prevent stroke in patients with AF is often 
not consistent with up-to-date guidelines which means that in some cases it is overused while 
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The GARFIELD-AF registry reported that in newly diagnosed atrial fibrillation, the rates of 
all major clinical events, which is death, stroke/systemic embolism and major bleeding, were 
significantly higher during the first month than in subsequent periods of follow-up at 2-4, 5-8 
and 9-12 months35. Cardiovascular events were mainly responsible for the increased all-cause 
mortality rate in the first month (3.5, 95% CI 3.0-4.1 per 100-person years), particularly 
congestive heart failure, acute coronary syndrome and sudden death while the rate of death of 
ischemic stroke was relatively low compared with oter causes of death (0.3, 95% CI 0.2-0.6 
per 100-person years)35.  It also confirms the dynamic nature of events given that ischemic 
stroke did not constitute the most common cause of early mortality.35 
 
Guidelines on risk re-assessment 
The 2014 American College of Cardiology (ACC), American Heart Association (AHA) and 
European Society of Cardiology (ESC) guidelines recommend the CHA2DS2-VASc score to 
assess stroke risk and indicate that the need for antico gulation should be re-evaluated at 
periodic intervals, but they do not specify their frequnecy.36 Moreover, the 2019 update of the 
AHA guidelines do not  provide any additional time frames in terms of stroke and bleeding 
risk reassessment.37  
The 2016 ESC guidelines recommend estimating stroke risk in AF patients based on 
CHA2DS2-VASc score. Because stroke and bleeding risk factors c mmonly overlap, many 
patients may be at increased risk of both, stroke and bleeding.38  The 2016 ESC guidelines 
emphasize the importance of comprehensive and structured approach to AF care with 
potential to improve outcomes. However, they do not provide broad-based and thorough 
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In terms of management, it should be focused on idetification and correction of individual 
bleeding risk factors rather than withholding OAC.38 
The 2018 Australia New Zealand clinical guidelines for the diagnosis and management of 
atrial fibrillation 2018 indicate that “the CHA2DS2-VASc score should be re- evaluated yearly 
in low-risk patients who are not anticoagulated.” 39    
Finally,  2018 CHEST Guideline and Expert Panel Report recommends for patients with AF, 
especially those at high risk (HAS-BLED score ≥3), use of the HAS-BLED score during 
every patient contact or review due to the highly dynamic bleeding risk.40  
 
Anticoagulation for all? 
The reason why OAC is not a default therapy for all AF patients lies in the perception that 
anticoagulation may cause harm in those at low risk, that is women with CHA2DS2-VASc 
score of 1 (perhaps 2) and men with the score of 0; however, there are no large randomized 
controlled trial to confirm this. Similarly, we do not have such high-quality data to evidently 
conclude that patients with the CHA2DS2-VASc score of 1 in women and zero in men are at 
truly low risk of stroke, given that risk changes with study setting, ethnicity, etc. Nonetheless, 
if the individualized annual stroke risk is assumed to be low (the threshold for the outcome 
will always be relative, subjective and may be argued), the net clinical benefit when balancing 
the stroke versus bleeding risk reduction may be negative.41 Importantly however, bleeding 
events are commonly less severe than a stroke is, and the use of OAC for stroke prevention 
aims at “event-free outcome”, in contrast to a bleeding event, which may/will appear in most 
of the patients over time. Moreover, the overall survival benefit with the use of OAC exceeds 
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the need for a holistic approach to AF care. Due to the potential risk of OAC use in truly low 
risk patients, other risk factors for stroke and bleeding may be considered, such as left atrial 
appendage morphology, biomarkers, genetics, intracranial vascular malformations etc.40  
However, this raises the issue about balancing improved risk prediction against simplicity and 




Due to dynamic nature of the cardiovascular risk factors which may influence treatment of AF 
patients, the assessment and management of these risk factors should also be dynamic.  A 
summary of evidence discussed in this review is given in Table 2. Hence, the decision-making 
pathway should be simplified and clear, involving bivariate analysis what allows to achieve 
best possible balance between stroke and bleeding risk.  Indeed, stroke and bleeding risk 
factors certainly ought to be reassessed at every patient contact. Moreover, optimal 
management of incident comorbidities should be provided due to the proven reduction of 
cardiovascular events via integrated care and optimized cardiovascular comorbidity treatment. 
Oral anticoagulants in the prevention of stroke in AF often are not adhered to current 
guidelines for under-use in patients at high risk of stroke and there is often over-prescription 
of them in low-risk individuals. Whether we need new or better guidelines or more extensive 
and successful implementation of current recommendations into clinical practice is an 
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Limitations 
Majority of analyzed studies were carried out in the Asian population, hence it is difficult to 
assess whether race and ethnic origin affect the risk score(s). 
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Table 1. Modifable and non-modifable risk factors for bleeding in anticoagulated 
patients based on bleeding risk scores. 
Modifiable bleeding risk factors 
Hypertension (especially when systolic blood pressure is >160 mmHg)a,b,c 
Labile INR or time in therapeutic range <60% in patients on vitamin K antagonists 
Medication predisposing to bleeding, such as antiplatelet drugs and non-steroidal anti-
inflammatory drugsa,d 
Excess alcohol (≥ 8 drinks/week)a,b 
Potentially modifiable bleeding risk factors 
Anaemiab,c,d 
Impaired renal functiona,b,c,d 
Impaired liver functiona,b 
Reduced platelet count or functionb 
Non-modifiable bleeding risk factors 
Age (>65 years)a (≥75 years)b,c,d 
History of major bleedinga,b,c,d 
Previous strokea,b 
Dialysis-dependent kidney disease or renal transplanta,c 
Cirrhotic liver diseasea 
Malignancyb 
Genetic factorsb 
Biomarker-based bleeding risk factors 
High-sensitivity troponine 
Growth differentiation factor-15e 
Serum creatinine/estimated CrCle 
 
 
aDerived from the HAS-BLED score.7 
bDerived from the HEMORR2HAGES score42 
cDerived from the ATRIA score.43 
dDerived from the ORBIT score.44 
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Figure 2. Cumulative incidence curves for increases in CHA2DS2-VASc score to ≥1 (men) or 










Figure 1. The AUCs of baseline, follow-up and delta scores in the prediction of ischemic 
stroke and major bleeding. The data used in the figure were from the papers by Chao 
et al.
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Figure 2. Cumulative incidence curves for increases in CHA2DS2-VASc score to ≥1 (men) or 
≥2 (women).
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